Pharmasset to Present at Two Upcoming Investor Conferences
Schaefer Price, Pharmasset's President and Chief Executive Officer, willprovide an overview of the company at the Rodman and Renshaw Conference onTuesday, November 11, 2008 at 12:25 PM (ET) and at the Lazard Capital MarketsConference on Tuesday November 18, 2008 at 8:55 AM (ET)
To access a simultaneous webcast of Mr. Price's overview via the internet,log on to the "Events & Presentations" section of the Investor Center onPharmasset's website at http://investor.pharmasset.com/events.cfm . Pleaseconnect to the website at least ten minutes prior to the start of thepresentation to ensure adequate time for a reliable connection and anysoftware download that may be necessary for the webcast.
A replay of the webcast will be available on Pharmasset's website forthirty days following the conference. The investor presentation will beavailable for download in PDF format immediately following the presentation inthe "Events & Presentations" section of the Investor Center on Pharmasset'swebsite at http://investor.pharmasset.com/events.cfm .
Pharmasset is a clinical-stage pharmaceutical company committed todiscovering, developing and commercializing novel drugs to treat viralinfections. Pharmasset's primary focus is on the development of oraltherapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus(HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,for the treatment of chronic HBV infection, is enrolling Phase 3 clinicaltrials for registration in North, Central and South America and Europe.Clevudine is already approved for HBV in South Korea and marketed by BukwangPharmaceuticals in South Korea under the brand name Levovir. R7128, an oraltreatment for chronic HCV infection, has completed a 4-week clinical trial incombination with Pegasys(R) plus Copegus(R) through a strategic collaborationwith Roche. Racivir, which is being developed for the treatment of HIV incombination with other approved HIV drugs, has completed a Phase 2 clinicaltrial.
Pharmasset "Safe Harbor" Statement under the Private Securities LitigationReform Act of 1995: Statements in this press release regarding our businessthat are not historical facts are "forward-looking statements" that involverisks and uncertainties, including without limitation, the risk that adverseevents could cause the cessation or delay of any of the ongoing or plannedclinical trials and/or our development of our product candidates, the riskthat the results of previously conducted studies involving our productcandidates will not be repeated or observed in ongoing or future studiesinvolving our product candidates, the risk that our collaboration with Rochewill not continue or will not be successful and the risk that any one or moreof our product candidates will not be successfully developed andcommercialized. For a discussion of these risks and uncertainties, any ofwhich could cause our actual results to differ from those contained in theforward-looking statements, see the section of our Annual Report on Form 10-Kfor the fiscal year ended September 30, 2007 filed with the Securities andExchange Commission entitled "Risk Factors" and discussions of potential risksand uncertainties in our subsequent filings with the Securities and ExchangeCommission.Pegasys(R) and Copegus(R) are registered trademarks of Roche. Contact Richard E. T. Smith, Ph.D. VP, Investor Relations and Corporate Communications firstname.lastname@example.org Office: +1 (609) 613-4181
SOURCE Pharmasset, Inc.
You May Also Like